@onclive.bsky.socialđź“° Just in: Epcoritamab plus R-CHOP improved PFS vs R-CHOP alone in newly diagnosed DLBCL, meeting the primary end point of the phase 3 EPCORE DLBCL-2 trial #lymsm #oncology
Dive into the topline findings: www.onclive.com/view/epcorit...
@societyofhemonc.bsky.social📢 Registration is open for the 4th SOHO-Israel Meeting! Nov 19–20, 2026, in person or online.
Register: hematology2026.forms-wizard.biz
Read more: sohoinsider.com/.../4th-soho...
#SOHO #Hematology #Oncology
@onclive.bsky.socialđź“° Botensilimab/balstilimab produced an estimated 3-year OS rate of 48% in heavily pretreated recurrent ovarian cancer in the ovarian cohort of the phase 1b C-800-01 trial. @danafarber.bsky.social #IGCS2026 #gyncsm #oncology
Read more ➡️: www.onclive.com/view/botensi...
@onclive.bsky.socialTreatment with PRV111, a cisplatin-releasing topical patch, led to a pCR rate of 95.5% in patients with noninvasive oral cancer or high-grade dysplasia in cohort 1 of the phase 2 portion of the ongoing CLN-004 trial #oncology
Read more: www.onclive.com/view/cisplat...
@onclive.bsky.socialIn an ongoing phase 1 dose-escalation study evaluating the FSHR-directed CAR T-cell therapy lira-cel, the first case of stable disease has been reported in a patient with recurrent ovarian cancer #ovca #oncology
Read more on the ongoing study: www.onclive.com/view/fshr-di...
@onclive.bsky.socialThe addition of the ATR inhibitor berzosertib to carboplatin failed to boost responses vs carboplatin with/without docetaxel in heavily pretreated mCRPC #pcsm #oncology
Dive into the phase 2 data here: www.onclive.com/view/berzose...
@wileyhealth.bsky.socialHalf of cancer patients in their 20s and 30s haven't started their families yet. Fewer than 5% go on to have children after treatment. 📉
Oncofertility is turning fertility preservation into a routine step in #CancerCare #Oncology.
👉 Learn more: https://bit.ly/3VJuYSx
@wiley-stem.bsky.socialHalf of cancer patients in their 20s and 30s haven't started their families yet. Fewer than 5% go on to have children after treatment. 📉
Oncofertility is turning fertility preservation into a routine step in #CancerCare #Oncology.
👉 Learn more: https://bit.ly/3V1wQWA
@bcc2026.bsky.social🎀 Breast Cancer Congress 2027
June 17–18, 2027
Zurich, Switzerland | Online participation available
Hosted by Sciinov Group
First Round Abstract Submission Ends: Oct 16, 2026
pinkribboncongress.com/abstract-sub...
#BreastCancer #Oncology #CancerResearch #BreastCancer2027 #MedicalConference
@scienceseminars.orgScience Seminar on 8 October 1 PM London / 8 AM EST with Prof. Jasmin Fisher (UCL): #Tumour digital twins for #precision #oncology. Please register at shorturl.at/qj46V
@ucl.ac.uk
@tumorijournal.bsky.social
@meducationai.bsky.socialYou can bring AI agents to your tumor board, and it's simpler than you think. Run a de-identified case, then take the literature into the real discussion. Free with OncoPulse.
@drjkyl.bsky.socialSensitivity and specificity of FDG-PET in detecting abdominopelvic disease in desmoplastic small round cell tumor
Rare Tumors
@journals.sagepub.com
@drjkyl.bsky.socialExtragastrointestinal stromal tumor involving the adrenal region: A rare case report
Rare Tumors
@journals.sagepub.com
@onclive.bsky.social🚨BREAKING: The @fda.gov has approved pirtobrutinib for adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma with no known 17p deletion #leusm #oncology
Read more: www.onclive.com/view/fda-app...
@axs-studio.com
@onclive.bsky.social🗞️ A @fda.gov NDA submission has been initiated for zipalertinib plus platinum-based chemotherapy in frontline, EGFR exon 20 insertion–positive NSCLC #lcsm #oncology
Dive into the REZILIENT3 data supporting the application: www.onclive.com/view/nda-sub...
@canceropolegso.bsky.socialđź’ˇ JGSO 2026
🎙️ Discover one of our keynotes for the 22nd Annual Meeting of the Cancéropôle Grand Sud-Ouest !
Find all information about the congress: kgso.fr/events/22nd-...
@onclive.bsky.social@onclive.bsky.social